ReviewInternational journal of nanomedicine2025
New Strategies for the Treatment of Diabetic Foot Ulcers Using Nanoenzymes: Frontline Advances in Anti-Infection, Immune Regulation, and Microenvironment Improvement.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immunomodulatory Tissue-Engineering Strategies for Diabetic Foot Ulcer Management: A Systematic Review.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair SocietyPooled it
- Investigation of the Efficacy and Mechanism of Monoacylglycerol Lipase Inhibitors in Diabetic Foot Ulcers.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Recent Advances in Nanozymes Toward Diabetic Foot Ulcers.International journal of nanomedicine · 2026Review
- Innovative microneedle-integrated hydrogels: a promising strategy for diabetic foot ulcer management.Frontiers in bioengineering and biotechnology · 2026Review
- FGFR2 is a Candidate Immune-Associated Marker of Diabetic Foot Ulcer That Promotes Keratinocyte Function by Activating the PI3K/Akt and MAPK Pathways.Mediators of inflammation · 2026Article
- Integrative neuromodulation in diabetic foot infections: electroacupuncture-driven macrophage reprogramming and synergy with antimicrobial biomaterials.Frontiers in cellular and infection microbiology · 2026Review
- Advanced Natural Therapeutics and Delivery Strategies for Diabetic Foot Ulcers: A Mini Review.Drug design, development and therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic foot ulcers are one of the most serious consequences of diabetes, arising from vascular impairment of the skin and disturbances in the microenvironment. This condition involves pathological changes such as wound infection, hyperglycemia, hypoxia, oxidative stress, and cellular dysfunction, necessitating multifaceted interventions. Traditional treatments often target only the wound itself, resulting in limited effectiveness. In contrast, nanoenzymes offer a promising therapeutic option due to their excellent biocompatibility and tissue permeability. They exhibit higher catalytic efficiency, optimal size and structure, and improved stability compared to natural enzymes. Encapsulating various nanoenzymes within novel biomaterials can enhance therapeutic outcomes through antibacterial action, glycemic control, oxygen delivery, antioxidative effects, anti-inflammatory properties, and angiogenesis promotion. This approach represents a key direction for future diabetic wound treatment. This article summarizes the role of nanoenzymes in diabetic wound management and discusses the potential mechanisms of their action. We also provide an outlook on their application prospects, aiming to advance their clinical utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.